Follow The Filings

GANX position history

The shares of Gain Therapeutics (GANX) that DME Capital Management reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2024 Q1: 566,130 shares, $2.1M, 0.10% of portfolio
  2. 2024 Q2: 566,130 shares, $725K, 0.04% of portfolio
  3. 2024 Q3: 566,130 shares, $1M, 0.04% of portfolio
  4. 2024 Q4: 566,130 shares, $1.2M, 0.06% of portfolio
  5. 2025 Q1: 566,130 shares, $1.1M, 0.05% of portfolio
  6. 2025 Q2: 566,130 shares, $1M, 0.04% of portfolio
  7. 2025 Q3: 566,130 shares, $1M, 0.04% of portfolio
  8. 2025 Q4: 566,130 shares, $1.8M, 0.06% of portfolio
  9. 2026 Q1: 566,130 shares, $1.1M, 0.03% of portfolio
  10. 2026 Q2: 566,130 shares, $1.1M, 0.03% of portfolio
  11. 2026 Q3: 566,130 shares, $979K, 0.03% of portfolio
Holdings date Value % of holdings Shares Filing date All 13F holders